Priority Review Criteria Reassessment Called For In FDA Rezulin Report

FDA's criteria for assigning priority review status should be re-evaluated, a Center for Drug Evaluation & Research Quality Assurance Staff report on the review of Warner-Lambert's Rezulin suggests.